PDF(Pubmed)
Abstract：
UNASSIGNED: Given a gradient relationship between fecal hemoglobin (f-Hb) concentration and colorectal neoplasia demonstrated previously, using f-Hb-guided interscreening interval has increasingly gained attention in population-based fecal immunological test (FIT), but it is very rare to address how to implement such a precision strategy and whether it can economize the use of FIT and colonoscopy.
UNASSIGNED: To demonstrate the applicability of personalized colorectal cancer (CRC) screening with f-Hb-guided screening intervals to reduce the number of FITs and colonoscopy with as equivalent efficacy as universal biennial screening.
UNASSIGNED: A retrospective cohort study for developing f-Hb-guided precision interscreening interval was conducted using data on a Taiwanese biennial nationwide FIT screening program that enrolled more than 3 million participants aged 50 to 74 years between 2004 and 2014. The cohort was followed up over time until 2019 to ascertain colorectal neoplasia and causes of death. A comparative study was further designed to compare the use of FIT and colonoscopy between the personalized f-Hb-guided group and the universal biennial screening group given the equivalent efficacy of reducing CRC-related outcomes.
UNASSIGNED: A spectrum of f-Hb-guided intervals was determined by using the Poisson regression model given the equivalent efficacy of a universal biennial screening. The use of FIT and colonoscopy for the pragmatic f-Hb-guided interval group was measured compared with the universal biennial screening group. Data analysis was performed from September 2022 to October 2023.
UNASSIGNED: Using data from the 3 500 250 participants (mean [SD] age, 57.8 [6.0] years) enrolled in the Taiwanese biennial nationwide FIT screening program, an incremental increase in baseline f-Hb associated with colorectal neoplasia and CRC mortality consistently was observed. Participants with different f-Hb levels were classified into distinct risk categories. Various screening intervals by different f-Hb levels were recommended. Using the proposed f-Hb-guided screening intervals, it was found that the personalized method was imputed to reduce the number of FIT tests and colonoscopies by 49% and 28%, respectively, compared with the universal biennial screening.
UNASSIGNED: The gradient relationship between f-Hb and colorectal neoplasia and CRC mortality was used to develop personalized FIT screening with f-Hb-guided screening intervals. Such a precision interscreening interval led to the reduced use of FIT test and colonoscopy without compromising the effectiveness of universal biennial screening.
UNASSIGNED: To demonstrate the applicability of personalized colorectal cancer (CRC) screening with f-Hb-guided screening intervals to reduce the number of FITs and colonoscopy with as equivalent efficacy as universal biennial screening.
UNASSIGNED: A retrospective cohort study for developing f-Hb-guided precision interscreening interval was conducted using data on a Taiwanese biennial nationwide FIT screening program that enrolled more than 3 million participants aged 50 to 74 years between 2004 and 2014. The cohort was followed up over time until 2019 to ascertain colorectal neoplasia and causes of death. A comparative study was further designed to compare the use of FIT and colonoscopy between the personalized f-Hb-guided group and the universal biennial screening group given the equivalent efficacy of reducing CRC-related outcomes.
UNASSIGNED: A spectrum of f-Hb-guided intervals was determined by using the Poisson regression model given the equivalent efficacy of a universal biennial screening. The use of FIT and colonoscopy for the pragmatic f-Hb-guided interval group was measured compared with the universal biennial screening group. Data analysis was performed from September 2022 to October 2023.
UNASSIGNED: Using data from the 3 500 250 participants (mean [SD] age, 57.8 [6.0] years) enrolled in the Taiwanese biennial nationwide FIT screening program, an incremental increase in baseline f-Hb associated with colorectal neoplasia and CRC mortality consistently was observed. Participants with different f-Hb levels were classified into distinct risk categories. Various screening intervals by different f-Hb levels were recommended. Using the proposed f-Hb-guided screening intervals, it was found that the personalized method was imputed to reduce the number of FIT tests and colonoscopies by 49% and 28%, respectively, compared with the universal biennial screening.
UNASSIGNED: The gradient relationship between f-Hb and colorectal neoplasia and CRC mortality was used to develop personalized FIT screening with f-Hb-guided screening intervals. Such a precision interscreening interval led to the reduced use of FIT test and colonoscopy without compromising the effectiveness of universal biennial screening.
摘要：
■鉴于先前证明的粪便血红蛋白（f-Hb）浓度与结直肠肿瘤之间的梯度关系，在基于人群的粪便免疫学测试（FIT）中，使用f-Hb引导的筛查间隔越来越受到关注，但如何实施这样的精准策略以及是否能节约FIT和结肠镜检查的使用却非常罕见.
■为了证明具有f-Hb指导的筛查间隔的个性化结直肠癌（CRC）筛查的适用性，以减少FIT和结肠镜检查的数量，其功效与通用两年期筛查的功效相同。
■使用台湾两年一次的全国性FIT筛查计划的数据进行了一项回顾性队列研究，该研究在2004年至2014年期间招募了超过300万名50至74岁的参与者。随着时间的推移，该队列一直随访到2019年，以确定结直肠肿瘤和死亡原因。进一步设计了一项比较研究，以比较个性化f-Hb指导组和通用两年期筛查组之间FIT和结肠镜检查的使用，以降低CRC相关结局的等效功效。
■通过使用泊松回归模型确定f-Hb引导间隔的频谱，该模型具有通用两年一次筛查的等效功效。与通用两年一次筛查组相比，对实用f-Hb引导间隔组的FIT和结肠镜检查的使用进行了测量。数据分析于2022年9月至2023年10月进行。
■使用来自3500250名参与者的数据(平均[SD]年龄，57.8[6.0]年)参加了台湾两年一次的全国FIT筛查计划，同时观察到基线f-Hb增加与结直肠肿瘤形成和CRC死亡率相关.具有不同f-Hb水平的参与者被分为不同的风险类别。建议通过不同的f-Hb水平进行各种筛选间隔。使用建议的f-Hb引导筛选间隔，结果发现，个性化的方法被估算，以减少49％和28％的FIT测试和结肠镜检查的数量，分别,与普遍的两年一次筛查相比。
■使用f-Hb与结直肠肿瘤和CRC死亡率之间的梯度关系来开发具有f-Hb指导筛选间隔的个性化FIT筛选。这种精确的间隔时间导致FIT测试和结肠镜检查的使用减少，而不会损害通用两年一次筛查的有效性。
■为了证明具有f-Hb指导的筛查间隔的个性化结直肠癌（CRC）筛查的适用性，以减少FIT和结肠镜检查的数量，其功效与通用两年期筛查的功效相同。
■使用台湾两年一次的全国性FIT筛查计划的数据进行了一项回顾性队列研究，该研究在2004年至2014年期间招募了超过300万名50至74岁的参与者。随着时间的推移，该队列一直随访到2019年，以确定结直肠肿瘤和死亡原因。进一步设计了一项比较研究，以比较个性化f-Hb指导组和通用两年期筛查组之间FIT和结肠镜检查的使用，以降低CRC相关结局的等效功效。
■通过使用泊松回归模型确定f-Hb引导间隔的频谱，该模型具有通用两年一次筛查的等效功效。与通用两年一次筛查组相比，对实用f-Hb引导间隔组的FIT和结肠镜检查的使用进行了测量。数据分析于2022年9月至2023年10月进行。
■使用来自3500250名参与者的数据(平均[SD]年龄，57.8[6.0]年)参加了台湾两年一次的全国FIT筛查计划，同时观察到基线f-Hb增加与结直肠肿瘤形成和CRC死亡率相关.具有不同f-Hb水平的参与者被分为不同的风险类别。建议通过不同的f-Hb水平进行各种筛选间隔。使用建议的f-Hb引导筛选间隔，结果发现，个性化的方法被估算，以减少49％和28％的FIT测试和结肠镜检查的数量，分别,与普遍的两年一次筛查相比。
■使用f-Hb与结直肠肿瘤和CRC死亡率之间的梯度关系来开发具有f-Hb指导筛选间隔的个性化FIT筛选。这种精确的间隔时间导致FIT测试和结肠镜检查的使用减少，而不会损害通用两年一次筛查的有效性。
